Global Albumin (Human) Market Size By Type (Injection, Freeze-dried Injection), By Application (Liver Diseases, Kidney Diseases), By Region, And Segment Forecasts, 2023 to 2032

The Global Albumin (Human) Market was valued at USD 5.2 billion in 2023 and is projected to reach USD 8.6 billion by 2031, growing at a CAGR of 6.7% during the forecast period from 2023 to 2031. Albumin, a vital plasma protein, is extensively used in clinical settings for treating shock, burns, hypoalbuminemia, and liver conditions, as well as in drug delivery systems and vaccine formulations. Rising prevalence of chronic liver diseases, growing number of surgical procedures, and increasing demand from biopharmaceutical and vaccine manufacturing are key contributors to market growth.

Drivers:

1. Increasing Prevalence of Liver and Kidney Disorders:

The growing incidence of conditions such as cirrhosis, nephrotic syndrome, and chronic kidney disease globally is propelling the demand for albumin infusions, particularly in Asia-Pacific and North America.

2. Rising Demand from the Biopharmaceutical Sector:

Albumin is widely used as a stabilizer and drug carrier in biopharmaceutical formulations. Its role in recombinant technologies and vaccine production has increased significantly, especially post-COVID-19.

3. Expanding Geriatric Population:

With the global rise in elderly populations, the need for medical interventions including albumin-based therapies is growing, as older adults are more prone to conditions like hypovolemia and hypoalbuminemia.

Restraints:

1. High Production Costs and Supply Constraints:

Human albumin production depends on plasma donations, which are limited. High purification and quality standards further elevate costs, creating supply-demand imbalances.

2. Stringent Regulatory Requirements:

Manufacturers must comply with strict regulatory guidelines for plasma-derived products, which can delay approvals and hinder product availability in certain regions.

Opportunity:

1. Innovations in Recombinant Albumin Production:

Emerging technologies for producing recombinant albumin offer scalable and virus-free alternatives to plasma-derived albumin, potentially revolutionizing the market.

2. Expanding Applications in Regenerative Medicine and Drug Delivery:

Albumin’s compatibility with stem cells and nanoparticle formulations is opening new avenues in targeted drug delivery, gene therapy, and tissue engineering.

Market by System Type Insights:

Therapeutic Albumin dominated the market in 2023, accounting for the largest revenue share due to its extensive use in hospitals for treating burns, trauma, surgeries, and liver-related complications. Meanwhile, Recombinant Albumin is emerging as the fastest-growing segment due to its growing utilization in advanced biopharmaceutical processes and cell culture applications.

Market by End-Use Insights:

Hospitals & Clinics held the largest market share in 2023, driven by high hospitalization rates, increased access to critical care, and a growing number of surgeries globally. Pharmaceutical & Biotechnology Companies are anticipated to witness the fastest growth, fueled by the increased use of albumin in drug formulation and vaccine stabilization.

Market by Regional Insights:

North America dominated the global albumin (human) market in 2023, owing to its robust healthcare infrastructure, high prevalence of chronic diseases, and strong presence of plasma collection centers. However, Asia-Pacific is projected to grow at the highest CAGR, supported by the increasing patient population, expanding healthcare access, and rising investments in plasma fractionation facilities in countries like China, India, and South Korea.

Competitive Scenario:

Major players in the Global Albumin (Human) Market include CSL Behring, Grifols S.A., Octapharma AG, Takeda Pharmaceutical Company Limited, Kedrion S.p.A., China Biologic Products Holdings, Inc., and Shanghai RAAS Blood Products Co., Ltd. These companies focus on expanding plasma collection capacities, advancing recombinant technologies, and securing strategic collaborations.

Key Developments:

In 2023, Grifols inaugurated a new plasma fractionation plant in North America to enhance supply chain efficiency and meet growing demand.

CSL Behring announced a partnership in 2024 with a leading biotech firm to co-develop recombinant albumin-based drug delivery platforms.

Octapharma expanded its manufacturing footprint in Europe in 2023, aiming to address albumin shortages in critical care applications.

Scope of Work – Global Albumin (Human) Market

Report Metric Details

Market Size (2023) USD 5.2 billion

Projected Market Size (2031) USD 8.6 billion

CAGR (2023–2031) 6.7%

Market Segments By System Type (Therapeutic, Recombinant), By End-use (Hospitals & Clinics, Pharma & Biotech), By Region

Growth Drivers Rising prevalence of liver disorders, increasing surgeries, growing demand in biologics

Opportunities Recombinant albumin R&D, application in drug delivery and regenerative medicine

FAQs:

1) What is the current market size of the Global Albumin (Human) Market?

The Global Albumin (Human) Market was valued at USD 5.2 billion in 2023.

2) What is the major growth driver of the Global Albumin (Human) Market?

The primary growth driver is the increasing prevalence of liver and kidney disorders along with rising demand in biopharmaceutical applications.

3) Which is the largest region during the forecast period in the Global Albumin (Human) Market?

North America is the largest region due to its developed healthcare system and high rate of albumin utilization.

4) Which segment accounted for the largest market share in Global Albumin (Human) Market?

The Therapeutic Albumin segment accounted for the largest market share in 2023.

5) Who are the key market players in the Global Albumin (Human) Market?

Key players include CSL Behring, Grifols S.A., Octapharma AG, Takeda, Kedrion, Shanghai RAAS, and China Biologic Products.

Let me know if you'd like this exported into a Word or PDF document!